Medical Condition News

RSS
New vibration technology to reduce stubborn stomach fat

New vibration technology to reduce stubborn stomach fat

Vanda Pharmaceuticals initiates tasimelteon Phase III clinical trial for Non-24-Hour Sleep Wake Disorder

Vanda Pharmaceuticals initiates tasimelteon Phase III clinical trial for Non-24-Hour Sleep Wake Disorder

Veterans Affairs partners with NIH to grant award for substance abuse research in military personnel

Veterans Affairs partners with NIH to grant award for substance abuse research in military personnel

National Kickoff Classic partners with Close the Gap campaign to raise heart disease risk factor awareness

National Kickoff Classic partners with Close the Gap campaign to raise heart disease risk factor awareness

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

Amneal Pharmaceuticals receives FDA approval for Spironolactone HCl tablets

Amneal Pharmaceuticals receives FDA approval for Spironolactone HCl tablets

Practice guideline-recommended care reduces bleeding in cirrhosis patients

Practice guideline-recommended care reduces bleeding in cirrhosis patients

Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule

Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule

New book on fighting hair loss

New book on fighting hair loss

Sermo report highlights physician opinions about investigational oral antiplatelet treatment for ACS

Sermo report highlights physician opinions about investigational oral antiplatelet treatment for ACS

Medtronic Ablation Frontiers Cardiac Ablation System receives Health Canada approval

Medtronic Ablation Frontiers Cardiac Ablation System receives Health Canada approval

DePuy Orthopaedics announces voluntary recall of ASR XL Acetabular and Hip Resurfacing systems

DePuy Orthopaedics announces voluntary recall of ASR XL Acetabular and Hip Resurfacing systems

Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF

Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

YFALS Campaign to appear in Milwaukee, Atlanta and Seattle

YFALS Campaign to appear in Milwaukee, Atlanta and Seattle

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

FDA notification confirms acyclovir Lauriad for oro-facial herpes labialis

FDA notification confirms acyclovir Lauriad for oro-facial herpes labialis

SOECIC announces UK's first operation to fit single cochlear implant to give sound in both ears

SOECIC announces UK's first operation to fit single cochlear implant to give sound in both ears

Octapharma completes clinical development of Uniplas human pooled plasma

Octapharma completes clinical development of Uniplas human pooled plasma

Tree Top enters Letter of Intent with WorldWithoutBlindness

Tree Top enters Letter of Intent with WorldWithoutBlindness

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.